MannKind: Patients have better view of insulin therapy when using Afrezza

SAN DIEGO — Patients with Type 1 diabetes using an insulin product made by MannKind expressed a better opinion about insulin therapy than those taking the standard treatment, according to a study presented at the American Diabetes Association’s 71st Scientific Sessions.

MannKind said that patients taking the investigational inhaled insulin Afrezza (insulin human [rDNA origin]) with basal insulin came to view insulin therapy more positively during the 16-week study than those taking Eli Lilly’s injected Humalog (insulin lispro [rDNA origin]) with basal insulin.

“The challenge of diabetes and its treatment can have a profound psychosocial impact on the patient, which must be addressed as part of managing the condition,” lead study investigator and Johns Hopkins University School of Medicine professor Richard Rubin said. “Current mealtime insulin therapy regimens require patients to titrate their insulin and use injections, both of which can negatively affect their perceptions of therapy and their long-term compliance.”